44 results on '"Huang, Jingcao"'
Search Results
2. Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma
- Author
-
Feng, Yu, Huang, Jingcao, Wang, Fangfang, Lin, Zhimei, Luo, Hongmei, Li, Qian, Wang, Xin, Liu, Xiang, Zhai, Xinyu, Gao, Qianwen, Li, Lingfeng, Zhang, Yue, Wen, Jingjing, Zhang, Li, Niu, Ting, and Zheng, Yuhuan
- Published
- 2023
- Full Text
- View/download PDF
3. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma
- Author
-
Luo, Hongmei, Feng, Yu, Wang, Fangfang, Lin, Zhimei, Huang, Jingcao, Li, Qian, Wang, Xin, Liu, Xiang, Zhai, Xinyu, Gao, Qianwen, Li, Lingfeng, Zhang, Yue, Wen, Jingjing, Zhang, Li, Niu, Ting, and Zheng, Yuhuan
- Published
- 2023
- Full Text
- View/download PDF
4. Single‐cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.
- Author
-
Wang, Xin, Feng, Yu, Wang, Fangfang, Lin, Zhimei, Huang, Jingcao, Li, Qian, Luo, Hongmei, Liu, Xiang, Zhai, Xinyu, Gao, Qianwen, Li, Linfeng, Zhang, Yue, Wen, Jingjing, Zhang, Li, Niu, Ting, and Zheng, Yuhuan
- Abstract
Aggrephagy, a type of autophagy, degrades the aggregation of misfolded protein in cells. However, the role of aggrephagy in multiple myeloma (MM) has not been fully demonstrated. In this study, we first investigated the correlation between aggrephagy signaling, MM immune microenvironment composition and disease prognosis. Single‐cell RNA‐seq data, including the expression profiles of 12,187 single cells from seven MM bone marrow (BM) and seven healthy BM samples, were analyzed by non‐negative matrix factorization for 44 aggrephagy‐related genes. Bulk RNA‐seq cohorts from the Gene Expression Omnibus database were used to evaluate the prognostic value of aggrephagy‐related immune cell subtypes and predict immune checkpoint blockade immunotherapeutic response in MM. Compared with healthy BM, MM BM exhibited different patterns of aggrephagy‐related gene expression. In MM BM, macrophages, CD8+ T cells, B cells and natural killer cells could be grouped into four to nine aggrephagy‐related subclusters. The signature of aggrephagy signaling molecule expression in the immune cells correlates with the patient's prognosis. Our investigation provides a novel view of aggrephagy signaling in MM tumor microenvironment cells, which might be a prognostic indicator and potential target for MM treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. ALCAM-EGFR interaction regulates myelomagenesis
- Author
-
Luo, Hongmei, Zhang, Dan, Wang, Fangfang, Wang, Qiang, Wu, Yu, Gou, Maling, Hu, Yiguo, Zhang, Wenyan, Huang, Jingcao, Gong, Yuping, Pan, Ling, Li, Tianshu, Zhao, Pan, Zhang, Danfeng, Qu, Ying, Liu, Zhigang, Jiang, Tao, Dai, Yang, Guo, Tingting, Zhu, Jiang, Ye, Lingqun, Zhang, Li, Liu, Weiping, Yi, Qing, and Zheng, Yuhuan
- Published
- 2021
- Full Text
- View/download PDF
6. High Wilms’ tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA
- Author
-
Naren, Duolan, Yan, Tianyou, Gong, Yuping, Huang, Jingcao, Zhang, Dan, Sang, Lina, Zheng, Xue, and Li, Yarong
- Published
- 2021
- Full Text
- View/download PDF
7. ALCAM regulates multiple myeloma chemoresistant side population
- Author
-
Wang, Fangfang, Dan, Zhang, Luo, Hongmei, Huang, Jingcao, Cui, Yushan, Ding, Hong, Xu, Juan, Lin, Zhimei, Gao, Yuhan, Zhai, Xinyu, Yang, Yan, Qu, Ying, Zhang, Li, Chen, Fengjiao, Wang, Qiang, Wang, Xin, Feng, Yu, Liu, Ting, Yi, Qing, Niu, Ting, and Zheng, Yuhuan
- Published
- 2022
- Full Text
- View/download PDF
8. Minimal residual disease in multiple myeloma: current status
- Author
-
Ding, Hong, Xu, Juan, Lin, Zhimei, Huang, Jingcao, Wang, Fangfang, Yang, Yan, Cui, Yushan, Luo, Hongmei, Gao, Yuhan, Zhai, Xinyu, Pang, Weicui, Zhang, Li, and Zheng, Yuhuan
- Published
- 2021
- Full Text
- View/download PDF
9. BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions
- Author
-
Zhang, Danfeng, Huang, Jingcao, Wang, Fangfang, Ding, Hong, Cui, Yushan, Yang, Yan, Xu, Juan, Luo, Hongmei, Gao, Yuhan, Pan, Ling, Wu, Yu, Gong, Yuping, Xie, Liping, Liu, Zhigang, Qu, Ying, Zhang, Li, Liu, Weiping, Zhang, Wenyan, Zhao, Sha, Yi, Qing, Niu, Ting, and Zheng, Yuhuan
- Published
- 2021
- Full Text
- View/download PDF
10. Young female patients with multiple myeloma have low occurrence of osteolytic lesion
- Author
-
Zhang, Danfeng, Huang, Jingcao, Zhang, Wenyan, Pan, Ling, Zhang, Dan, Zhao, Pan, Wang, Fangfang, Luo, Hongmei, He, Jin, Qin, Yu, Qu, Ying, Guo, Tingting, Niu, Ting, and Zheng, Yuhuan
- Published
- 2018
- Full Text
- View/download PDF
11. Wharton’s jelly mesenchymal stem cell-based or umbilical vein endothelial cell-based serum-free coculture with cytokines supports the ex vivo expansion/maintenance of cord blood hematopoietic stem/progenitor cells
- Author
-
Li, Qiuyang, Zhao, Dewan, Chen, Qiang, Luo, Maowen, Huang, Jingcao, Yang, Cao, Wang, Fangfang, Li, Wenxian, and Liu, Ting
- Published
- 2019
- Full Text
- View/download PDF
12. Epigenetic mechanism of survivin dysregulation in human cancer
- Author
-
Lyu, Hui, Huang, Jingcao, He, Zhimin, and Liu, Bolin
- Published
- 2018
- Full Text
- View/download PDF
13. Therapeutic effect of 28-homobrassinolide on leukotriene synthesis in leukemia cells
- Author
-
He, Chuan, Liu, Zhigang, Huang, Jingcao, and Liu, Ting
- Published
- 2018
- Full Text
- View/download PDF
14. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia
- Author
-
Huang, Jingcao, Lyu, Hui, Wang, Jianxiang, and Liu, Bolin
- Published
- 2015
- Full Text
- View/download PDF
15. Condition monitoring and fault diagnosis of hydropower generator based on LSTM correction model.
- Author
-
Huang, Jingcao, Guo, Bin, and Dian, Songyi
- Subjects
- *
FAULT diagnosis , *HEALTH status indicators , *PREDICTION models - Abstract
Hydropower station is vital for the stable growth of the national economy. How to timely warn the possible faults of hydropower stations has become an increasingly popular research topic. The traditional detection model is difficult to detect the small abnormal changes in the data, and these abnormal changes are often the precursor of faults. To improve the sensitivity of the traditional detection model, this study introduced a weight factor into the traditional LSTM detection model. By using the correction mechanism, the LSTM correction model makes the prediction model never deviate from the normal track following the appearance of abnormal data. This ensures that the model can generate large residuals after abnormal data occur so that we can detect these abnormal data in time. Finally, this paper puts forward two factors related to equipment health and integrates these two factors to form a health index. The results show that the LSTM correction model based on the health index can not only detect small changes that cannot be detected by traditional detection models but also knows the wear and tear of equipment during operation based on the changes in health indicators. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors—a Study in Leukemia Cells
- Author
-
Dai, Yang, Huang, Jingcao, Xiang, Bing, Zhu, Huanling, and He, Chuan
- Published
- 2018
- Full Text
- View/download PDF
17. Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
- Author
-
Lyu, Hui, Huang, Jingcao, He, Zhimin, and Liu, Bolin
- Published
- 2018
- Full Text
- View/download PDF
18. Hypoxia with Wharton’s jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells
- Author
-
Zhao, Dewan, Liu, Lingjia, Chen, Qiang, Wang, Fangfang, Li, Qiuyang, Zeng, Qiang, Huang, Jingcao, Luo, Maowen, Li, Wenxian, Zheng, Yuhuan, and Liu, Ting
- Published
- 2018
- Full Text
- View/download PDF
19. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response
- Author
-
Cai, Bo, Lyu, Hui, Huang, Jingcao, Wang, Shuiliang, Lee, Choon-Kee, Gao, Chunji, and Liu, Bolin
- Published
- 2013
- Full Text
- View/download PDF
20. Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity.
- Author
-
Lin, Zhimei, Chu, Bingyang, Qu, Ying, Wei, Xue, Huang, Jingcao, Wang, Fangfang, Feng, Yu, Wang, Xin, Luo, Hongmei, Zhai, Xinyu, Xu, Juan, Liu, Xiang, Zhang, Li, Chen, Fengjiao, Wu, Yu, and Zheng, Yuhuan
- Published
- 2023
- Full Text
- View/download PDF
21. Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.
- Author
-
Qu, Ying, Chu, Bingyang, Wei, Xue, Chen, Yingying, Yang, Yun, Hu, Danrong, Huang, Jingcao, Wang, Fangfang, Chen, Mengran, Zheng, Yuhuan, and Qian, Zhiyong
- Published
- 2022
- Full Text
- View/download PDF
22. Estrogen‐Responsive Gene MAST4 Regulates Myeloma Bone Disease.
- Author
-
Cui, Yushan, Wang, Fangfang, Zhang, Danfeng, Huang, Jingcao, Yang, Yan, Xu, Juan, Gao, Yuhan, Ding, Hong, Qu, Ying, Zhang, Wenyan, Liu, Weiping, Pan, Ling, Zhang, Li, Liu, Zhigang, Niu, Ting, Liu, Ting, and Zheng, Yuhuan
- Abstract
Our previous data showed that young female multiple myeloma (MM) patients had a low frequency of osteolytic lesions. Based on this clinical observation, we found that estrogen cell signaling played a regulatory role in MM bone disease (MMBD), and the estrogen‐responsive gene microtubule‐associated serine/threonine kinase family member 4 (MAST4) was a critical factor. The presence of estrogen in cell cultures promoted MAST4 expression in MM cells, while knocking down estrogen receptor 1 (ESR1) inhibited MAST4 expression. Chromatin immunoprecipitation assay suggested a binding site of ESR1 on the MAST4 promoter. Bisphosphonates, such as zoledronic acid (ZOL), which was widely used in MMBD control, could stimulate MAST4 expression in MM cells by promoting ESR1 expression. MAST4 interacted with phosphatase and tensin homolog (PTEN), therefore regulating the PI3K‐Akt‐mTOR pathway and the expression of downstream cytokines, such as CCL2/3/4. MAST4 knockdown (MAST4‐KD) or ESR1 knockdown (ESR1‐KD) MM cells had repressed PTEN activity, elevated PI3K‐Akt‐mTOR activity, and increased CCL2/3/4 expressions. Coculture of MAST4‐KD or ESR1‐KD MM cells with pre‐osteoclasts (pre‐OCs) stimulated OC formation in vitro, whereas neutralizing antibodies of CCL2/3/4 attenuated such stimulation. In mouse models, mice inoculated with MAST4‐KD or ESR1‐KD MM cells had severer MMBD than control knockdown (CTR‐KD). The correlations between MAST4 and ESR1 expressions in MMBD, as well as related cell signaling pathways, were confirmed in analyses using gene expression profiles (GEPs) of patients' MM cells. The negative correlation of MAST4 expression and occurrence of MMBD was further validated by patients' immunohistochemical tissue array. Overall, our data suggested that estrogen cell signaling negatively regulated MMBD through MAST4. © 2022 American Society for Bone and Mineral Research (ASBMR). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. ISG20L2 Suppresses Bortezomib Anti-Myeloma Activity By Attenuating Bortezomib Binding to PSMB5
- Author
-
Yang, Yan, Gao, Yuhan, Huang, Jingcao, Niu, Ting, and Zheng, Yuhuan
- Published
- 2022
- Full Text
- View/download PDF
24. Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.
- Author
-
Xu, Juan, Yu, Nanhui, Zhao, Pan, Wang, Fangfang, Huang, Jingcao, Cui, Yushan, Ding, Hong, Yang, Yan, Gao, Yuhan, Pan, Ling, Chang, Hong, Wu, Yu, Xiang, Bing, Gong, Yuping, Shuai, Xiao, Hou, Li, Xie, Liping, Niu, Ting, Liu, Ting, and Zhang, Li
- Subjects
EXTRAMEDULLARY diseases ,MACROPHAGE migration inhibitory factor ,HISTOLOGY ,INFECTIOUS disease transmission ,MULTIPLE myeloma ,PLASMACYTOMA ,PLASMA cell diseases - Abstract
Macrophage migration inhibitory factor (MIF) has been shown to promote disease progression in many malignancies, including multiple myeloma (MM). We previously reported that MIF regulates MM bone marrow homing and knockdown of MIF favors the extramedullary myeloma formation in mice. Here, based on MIF immunostaining of myeloma cells in paired intramedullary and extramedullary biopsies from 17 patients, we found lower MIF intensity in extramedullary MM (EMM) versus intramedullary MM (IMM). Flow cytometry and histology analysis in xenograft models showed a portion of inoculated human MM cells lost their MIF expression (MIF
Low ) in vivo. Of note, IMM had dominantly MIFHigh cells, while EMM showed a significantly increased ratio of MIFLow cells. Furthermore, we harvested the extramedullary human MM cells from a mouse and generated single-cell transcriptomic data. The developmental trajectories of MM cells from the MIFHigh to MIFLow state were indicated. The MIFHigh cells featured higher proliferation. The MIFLow ones were more quiescent and harbored abundant ribosomal protein genes. Our findings identified in vivo differential regulation of MIF expression in MM and suggested a potential pathogenic role of MIF in the extramedullary spread of disease. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
25. PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.
- Author
-
Luo, Hongmei, Sun, Ruixue, Zheng, Yuhuan, Huang, Jingcao, Wang, Fangfang, Long, Dan, and Wu, Yu
- Subjects
ACUTE myeloid leukemia ,WESTERN immunoblotting ,CELL migration ,POLYMERASE chain reaction ,CELL lines - Abstract
Purpose: Acute myeloid leukemia (AML) is associated with a poor overall prognosis. PIM family genes, including PIM1, PIM2, and PIM3, are proto-oncogenes that are aberrantly overexpressed in different types of human cancers. In this study, we aimed to explore and clarify the function of PIM3 in AML. Patients and Methods: The expression of the three PIM genes in AML was detected using the Gene Expression Omnibus. The expression of PIM3 and PIM3 in patient samples and AML cell lines was measured using quantitative real-time polymerase chain reaction or Western blot analyses. The cellular behaviors of PIM3-overexpressing AML cell lines were detected using a CCK-8 assay, flow cytometry, Western blotting, immunofluorescence staining, and a cell migration assay. The interactions between PIM3 and phosphorylated CXCR4 (pCXCR4) were explored via immunoprecipitation. Results: Higher PIM3 expression was detected in primary AML cells than in healthy donor cells. Second, PIM3 overexpression promoted AML cell proliferation and protected against spontaneous apoptosis by phosphorylating BAD (pBAD) at Ser112. Furthermore, PIM3 overexpression might promote the migration of AML cells via CXCR4. PIM3-overexpressing AML cell lines exhibited increased CXCR4 phosphorylation at Ser339, and pCXCR4 interacted with PIM3. Conclusion: Our findings suggest that PIM3 regulates the proliferation, survival, and chemotaxis of AML cell lines. Moreover, pCXCR4 might mediate the regulation of PIM3-induced chemotaxis. Therefore, the inhibition of PIM3 expression may be a promising therapeutic target in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. MicroRNA regulation and therapeutic targeting of survivin in cancer
- Author
-
Huang, Jingcao, Lyu, Hui, Wang, Jianxiang, and Liu, Bolin
- Subjects
Review Article ,neoplasms - Abstract
Survivin, the smallest member of IAP (inhibitor of apoptosis) family, is a dual functional protein acting as a critical apoptosis inhibitor and key cell cycle regulator. Survivin is usually expressed in embryonic tissues during development and undetectable in most terminally differentiated tissues. Numerous studies demonstrate that survivin is selectively upregulated in almost all types of human malignancies and its overexpression positively correlates with poor prognosis, tumor recurrence, and therapeutic resistance. This differential expression of survivin in tumors and normal tissues draws a great interest to develop survivin-targeted therapy for cancer treatment. Nonetheless, the molecular mechanisms controlling survivin expression in malignant tumor cells have not been fully understood. While aberrant activation of receptor tyrosine kinases (RTKs) and the downstream signaling, such as PI-3K/Akt, MEK/MAPK, mTOR, and STAT pathways, have frequently been shown to upregulate survivin, recent data suggest that a class of noncoding RNAs, microRNAs (miRNAs) also play an important role in survivin dysregulation in human cancers. Here, we focus on survivin expression-regulated by specific miRNAs binding to the 3'-UTR of survivin mRNA, and summarize the latest advances on survivin-targeted therapy in clinical trials and the therapeutic potential of survivin-targeting miRNAs in cancer.
- Published
- 2014
27. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
- Author
-
Li, Qing, Huang, Jingcao, Ou, Yang, Li, Yan, and Wu, Yu
- Published
- 2019
- Full Text
- View/download PDF
28. SLC2A5 overexpression in childhood philadelphia chromosome‐positive acute lymphoblastic leukaemia.
- Author
-
Zhao, Pan, Huang, Jingcao, Zhang, Dan, Zhang, Danfeng, Wang, Fangfang, Qu, Ying, Guo, Tingting, Qin, Yu, Wei, Jin, Niu, Ting, and Zheng, Yuhuan
- Subjects
- *
LYMPHOBLASTIC leukemia , *MESSENGER RNA , *GENE expression , *DASATINIB , *ANTINEOPLASTIC agents , *ENDOCRINOLOGY - Abstract
Summary: To study glycolysis/glycogenesis‐related genes expression in childhood B‐cell acute lymphoblastic leukaemia (B‐ALL), we performed a microarray‐based analysis using published gene expression profiles. We found that SLC2A5, which encodes solute carrier family 2 member 5 (SLC2A5, previously termed GLUT5) that facilitates cell fructose uptake, was up‐regulated in Philadelphia chromosome‐positive ALL (Ph+ALL). Microarray‐based analyses also suggested that SLC2A5 expression was significantly down‐regulated in childhood B‐ALL with t(1;19) or 11q23 mutation. High SLC2A5 expression was found in patients who had disease recurrence within 3 years, early relapse, shortened complete remission duration and positive minimal residue disease (MRD) status after treatment. SLC2A5 overexpression at both the mRNA and protein level in Ph+ALL was confirmed in a validation cohort of childhood B‐ALL. We also validated the correlation of SLC2A5 expression and MRD status. A mechanistic study using a human Ph+ALL cell line showed that BCR‐ABL1 kinase might regulate SLC2A5 expression via MYC. The tyrosine kinase inhibitors (TKIs) imatinib and dasatinib repressed SLC2A5 expression and the cell uptake of fructose. Fructose protected the tumour cells from nutrition deficiency and drug‐induced cell death. Overall, our findings showed that SLC2A5 was up‐regulated in childhood Ph+ALL. SLC2A5 expression correlated with childhood B‐ALL clinical factors, such as MRD status. Given that TKIs could inhibit SLC2A5 expression, repression of fructose utility after TKI treatment contributes to TKI‐induced Ph+ALL cytotoxicity. Targeting SLC2A5 might be promising in B‐ALL treatment, especially for Ph+ALL patients with high SLC2A5 expression. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Role of erbB3 receptors in cancer therapeutic resistance.
- Author
-
Lee, Youngseok, Ma, Jian, Lyu, Hui, Huang, Jingcao, Kim, Aeree, and Liu, Bolin
- Published
- 2014
- Full Text
- View/download PDF
30. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
- Author
-
Wang, Fangfang, Huang, Jingcao, Guo, Tingting, Zheng, Yuhuan, Zhang, Li, Zhang, Dan, Wang, Fujue, Naren, Duolan, Cui, Yushan, Liu, Xiaoyan, Qu, Ying, Luo, Hongmei, Yang, Yan, Wei, Haichen, and Guo, Yong
- Subjects
- *
ACUTE myeloid leukemia , *CELL cycle , *ALDEHYDE dehydrogenase , *BAX protein , *PROGNOSIS - Abstract
[Display omitted] Acute myeloid leukemia (AML) with FLT3 internal tandem duplication (FLT3 -ITD) has a dismal prognosis. FLT3 inhibitors have been developed to treat patients with FLT3 -ITD AML; however, when used alone, their efficacy is insufficient. FLT3 inhibitors combined with chemotherapy may be a promising treatment for FLT3 -ITD AML. Homoharringtonine (HHT) is a classical anti-leukaemia drug with high sensitivity to FLT3 -ITD AML cells. Here, we showed that HHT synergizes with a selective next-generation FLT3 inhibitor, quizartinib, to inhibit cell growth/viability and induce cell-cycle arrest and apoptosis in FLT3 -ITD AML cells in vitro, significantly inhibit acute myeloid leukemia progression in vivo, and substantially prolong survival of mice-bearing human FLT3 -ITD AML. Mechanistically, HHT and quizartinib cooperatively inhibit FLT3-AKT and its downstream targets GSK3β, c-Myc, and cyclin D1, cooperatively up-regulate the pro-apoptosis proteins Bim and Bax, and down-regulate the anti-apoptosis protein Mcl1. Most strikingly, HHT and quizartinib cooperatively reduce the numbers of side-population (SP) and aldehyde dehydrogenase (ALDH)-positive cells, which reportedly are rich in LSCs. In conclusion, HHT combined with quizartinib may be a promising treatment strategy for patients with FLT3 -ITD AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
- Author
-
Lin, Zhimei, Zhang, Yue, Liu, Xiang, Luo, Hongmei, Li, Qian, Gao, Qianwen, Wang, Xin, Wen, Jingjing, Li, Linfeng, Feng, Yu, Wang, Fangfang, Huang, Jingcao, Zhai, Xinyu, Zhang, Li, Niu, Ting, and Zheng, Yuhuan
- Abstract
Summary Multiple myeloma (MM) is an incurable plasma cell cancer in the bone marrow. Immunomodulatory drugs, such as lenalidomide (LEN) and pomalidomide, are backbone agents in MM treatment, and LEN resistance is commonly seen in the MM clinic. In this study, we presented that heterogeneous nuclear ribonucleoprotein U (hnRNPU) affected MM resistance to LEN via the regulation of target mRNA translation. hnRNPULow MM cells exhibited upregulated CRBN and IKZF1 proteins, stringent IKZF1/3 protein degradation upon LEN addition and increased sensitivity to LEN. RNA pulldown assays and RNA electrophoretic mobility shift assays revealed that hnRNPU bound to the 3′‐untranslated region of CRBN and IKZF1 mRNA. A sucrose gradient assay suggested that hnRNPU specifically regulated CRBN and IKZF1 mRNA translation. The competition of hnRNPU binding to its target mRNAs by small RNAs with hnRNPU‐binding sites restored MM sensitivity to LEN. hnRNPU function in vivo was confirmed in an immunocompetent MM mouse model constructed by the inoculation of Crbn‐humanized murine 5TGM1 cells into CrbnI391V/+ mice. Overall, this study suggests a novel mechanism of LEN sensitivity in which hnRNPU represses CRBN and IKZF1 mRNA translation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells.
- Author
-
Zhao, Dewan, Liu, Lingjia, Chen, Qiang, Wang, Fangfang, Li, Qiuyang, Zeng, Qiang, Huang, Jingcao, Luo, Maowen, Li, Wenxian, Zheng, Yuhuan, and Liu, Ting
- Subjects
MESENCHYMAL stem cells ,HYPOXEMIA ,CORD blood ,HEMATOPOIETIC stem cells ,PHENOTYPES ,MESSENGER RNA ,VASCULAR endothelial growth factors - Abstract
Background: The physiological approach suggests that an environment associating mesenchymal stromal cells with low O
2 concentration would be most favorable for the maintenance of hematopoietic stem/progenitor cells (HSPCs). To test this hypothesis, we performed a coculture of cord blood CD34+ cells with Wharton's jelly mesenchymal stem cells (WJ-MSCs) under different O2 concentration to simulate the growth of HSPCs in vivo, and assessed the impacts on stemness maintenance and proliferation of cord blood HSPCs in vitro. Methods: CD34+ cells derived from cord blood were isolated and cocultured under 1%, 3%, or 20% O2 concentrations with irradiated WJ-MSCs without adding exogenous cytokines for 7 days. The cultured cells were harvested and analyzed for phenotype and functionality, including total nuclear cells (TNC), CD34+ Lin− cells, colony forming unit (CFU) for committed progenitors, and long-term culture initiating cells (LTC-ICs) for HSPCs. The cytokine levels in the medium were detected with Luminex liquid chips, and the mRNA expression of hypoxia inducible factor (HIF) genes and stem cell signal pathway (Notch, Hedgehog, and Wnt/β-catenin) downstream genes in cord blood HSPCs were confirmed by quantitative real-time polymerase chain reaction (qRT-PCR). Results: Our results showed that the number of TNC cells, CD34+ Lin− cells, and CFU were higher or similar with 20% O2 (normoxia) in coculture and compared with 1% O2 (hypoxia). Interestingly, a 1% O2 concentration ensured better percentages of CD34+ Lin− cells and LTC-IC cells. The hypoxia tension (1% O2 ) significantly increased vascular endothelial growth factor (VEGF) secretion and decreased interleukin (IL)-6, IL-7, stem cell factor (SCF), and thrombopoietin (TPO) secretion of WJ-MSCs, and selectively activated the Notch, Wnt/β-catenin, and Hedgehog signaling pathway of cord blood HSPCs by HIF-related factors, which may play an important role in stemness preservation and for sustaining HSPC quiescence. Conclusions: Our data demonstrate that cord blood HSPCs maintain stemness better under hypoxia than normoxia with WJ-MSC coculture, partially due to the increased secretion of VEGF, decreased secretion of IL-6 by WJ-MSCs, and selective activation of stem cell signal pathways in HSPCs. This suggests that the oxygenation may not only be a physiological regulatory factor but also a cell engineering tool in HSPC research, and this may have important translational and clinical implications. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
33. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
- Author
-
Lyu, Hui, Wang, Shuiliang, Huang, Jingcao, Wang, Bolun, He, Zhimin, and Liu, Bolin
- Subjects
- *
SURVIVIN (Protein) , *GENE expression , *MOLECULAR genetics , *DEADENYLATION , *TRANSCRIPTION factors , *ANIMAL experimentation , *BIOCHEMISTRY , *BREAST tumors , *CELL lines , *CELL receptors , *CELLULAR signal transduction , *COMPARATIVE studies , *DRUG resistance in cancer cells , *GENES , *INDUSTRIES , *PHENOMENOLOGY , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PACLITAXEL , *RESEARCH , *RESEARCH funding , *RNA , *EVALUATION research , *PHARMACODYNAMICS - Abstract
Elevated expression of HER3, which interacts with HER2 in breast cancer cells, confers chemoresistance via phosphoinositide 3-kinase (PI-3K)/Akt-dependent upregulation of Survivin. However, the underlying mechanism is not clear. Ectopic expression or specific knockdown of HER3 in HER2-overexpressing breast cancer cells did not alter Survivin mRNA levels and Survivin protein stability, supporting the notion that HER3 signaling may regulate specific miRNAs that target Survivin to alter its protein translation. Here we showed that overexpression and specific knockdown of HER3 reduced and enhanced expression of two Survivin-targeting miRNAs, miR-203 and miR-542-3p, in breast cancer cells, respectively. While the specific inhibitor of either miR-203 or miR-542-3p attenuated an anti-HER3 antibody-induced downregulation of Survivin, inhibition of miR-542-3p exhibited a better efficacy than miR-203 inhibition did. Consistently, miR-542-3p mimic was much more effective than miR-203 mimic not only in inhibition of Survivin, but also in enhancement of paclitaxel-induced apoptosis in HER2-overexpressing breast cancer cells. Moreover, the combination of miR-542-3p mimic and paclitaxel, as compared with either agent alone, significantly inhibited in vivo tumor growth of HER2-overexpressing breast cancer cells. Collectively, our data indicated that the HER3/PI-3K/Akt signaling upregulates Survivin via suppression of miR-203 and miR-542-3p. Because miR-542-3p has three binding sites on the 3'-UTR of Survivin mRNA, its mimic was able to effectively downregulate Survivin in vitro and in vivo. Thus, miR-542-3p-replacement therapy is an excellent approach to overcome HER3-mediated paclitaxel resistance and significantly enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
- Author
-
Wang, Shuiliang, Huang, Jingcao, Lyu, Hui, Cai, Bo, Yang, Xiaoping, Li, Fang, Tan, Jianming, Edgerton, Susan M, Thor, Ann D, Lee, Choon-Kee, and Liu, Bolin
- Abstract
Introduction: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin. It is unclear whether an erbB3-targeted therapy may abrogate erbB2-mediated paclitaxel resistance in breast cancer. Here, we study the antitumor activity of an anti-erbB3 antibody MM-121/SAR256212 in combination with paclitaxel against erbB2-overexpressing breast cancer.Methods: Cell growth assays were used to determine cell viability. Cells undergoing apoptosis were quantified by a specific apoptotic ELISA. Western blot analyses were performed to assess the protein expression and activation. Lentiviral vector containing shRNA was used to specifically knockdown Survivin. Tumor xenografts were established by inoculation of BT474-HR20 cells into nude mice. The tumor-bearing mice were treated with paclitaxel and/or MM-121/SAR256212 to determine whether the antibody (Ab) enhances paclitaxel’s antitumor activity. Immunohistochemistry was carried out to study the combinatorial effects on tumor cell proliferation and induction of apoptosis in vivo.Results: MM-121 significantly facilitated paclitaxel-mediated anti-proliferative/anti-survival effects on SKBR3 cells transfected with a control vector or erbB3 cDNA. It specifically downregulated Survivin associated with inactivation of erbB2, erbB3, and Akt. MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of caspase-8 and −3, and apoptosis in both paclitaxel-sensitive and -resistant cells. Specific knockdown of Survivin in the trastuzumab-resistant BT474-HR20 cells dramatically enhanced paclitaxel-induced apoptosis, suggesting that increased Survivin caused a cross-resistance to paclitaxel. Furthermore, the studies using a tumor xenograft model-established from BT474-HR20 cells revealed that either MM-121 (10 mg/kg) or low-dose (7.5 mg/kg) paclitaxel had no effect on tumor growth, their combinations significantly inhibited tumor growth in vivo. Immunohistochemical analysis showed that the combinations of MM-121 and paclitaxel significantly reduced the cells with positive staining for Ki-67 and Survivin, and increased the cells with cleaved caspase-3.Conclusions: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2-overexpressing breast cancers. Our data supports further exploration of the combinatorial regimens consisting of MM-121 and paclitaxel in breast cancer patients with erbB2-overexpressing tumors, particularly those resistant to paclitaxel. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
35. Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity.
- Author
-
Lin Z, Chu B, Qu Y, Wei X, Huang J, Wang F, Feng Y, Wang X, Luo H, Zhai X, Xu J, Liu X, Zhang L, Chen F, Wu Y, and Zheng Y
- Abstract
Multiple myeloma (MM), a plasma cell cancer in bone marrow, remains an incurable disease. Melphalan, an alkylating agent, is a conventional anticancer drug that is still widely used for MM treatment in clinics. However, melphalan-induced organ toxicity and side effects are common. In this study, we loaded melphalan into a liposomal capsule and constituted liposomal melphalan (liposomal MEL). Liposomal MEL particles were approximately 120 nm in size and stable in vitro . The liposomal particles could be effectively taken up by MM cells. In vitro cytotoxicity assays using MM cell lines and primary MM cells showed that liposomal MEL exhibited similar anti-MM activity compared to an equivalent amount of free melphalan (free MEL) compound. In animal models, liposomal particles had bone marrow enrichment and prolonged half-life in vivo . Liposomal MEL exposure resulted in less liver and colon organ toxicity than exposure to an equivalent amount of free MEL-treated mice. Importantly, liposomal MEL had potent anti-MM activity in vivo in a human MM xenograft mouse model. Overall, our findings suggested that liposome-encapsulated melphalan was an effective drug modification of the melphalan compound and showed promise in MM treatment., Competing Interests: The authors declare no competing financial interest., (© 2022 The Authors. Published by American Chemical Society.)
- Published
- 2022
- Full Text
- View/download PDF
36. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
- Author
-
Yang Y, Gao Y, Huang J, Yang Z, Luo H, Wang F, Xu J, Cui Y, Ding H, Lin Z, Zhai X, Qu Y, Zhang L, Liu T, Ye L, Niu T, and Zheng Y
- Subjects
- Boronic Acids pharmacology, Bortezomib pharmacology, Bortezomib therapeutic use, Cell Line, Tumor, Drug Resistance, Neoplasm, Exonucleases, Humans, Interferons, Proteasome Endopeptidase Complex metabolism, Pyrazines, Multiple Myeloma drug therapy, Proteasome Inhibitors pharmacology
- Abstract
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment. In this study, we demonstrated the role of interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) in MM PI resistance. Gain- and loss-of-function studies showed that ISG20L2 suppressed MM cell sensitivity to PIs in vitro and in vivo. Patients with ISG20L2lo MM had a better response to PIs and a longer overall survival than patients with ISG20L2hi MM. Biotinylated bortezomib pull-down assays showed that ISG20L2 competed with PSMB5 in binding to bortezomib. The surface plasmon resonance assay confirmed the direct binding of bortezomib to ISG20L2. In ISG20L2hi MM cells, ISG20L2 attenuated the binding of bortezomib to PSMB5, resulting in lower inhibition of proteasome activity and therefore less bortezomib-induced cell death. Overall, we identified a potentially novel mechanism by which ISG20L2 conferred bortezomib resistance on MM. The expression of ISG20L2 correlated with MM PI responses and patient treatment outcomes.
- Published
- 2022
- Full Text
- View/download PDF
37. A novel immune prognostic model of non-M3 acute myeloid leukemia.
- Author
-
Ding H, Feng Y, Xu J, Lin Z, Huang J, Wang F, Luo H, Gao Y, Zhai X, Wang X, Zhang L, Niu T, and Zheng Y
- Abstract
Acute myeloid leukemia (AML) is a common hematological malignancy in adults. AML patients exhibit clinical heterogeneity with complications of molecular basis. The leukemogenesis of AML involves immune escape, and the immunosuppression status of the patient might have great impact on AML treatment outcome. In this study, we established an immune prognostic model of AML using bioinformatics tools. With the data in the TCGA and GTEx datasets, we analyzed differentially expressed genes (DEGs) in non-M3 AML and identified 420 immune-related DEGs. Among which, 49 genes' expression was found to be related to AML prognosis based on univariate Cox regression analysis. Next, we established a prognostic model with these 49 genes in AML by LASSO regression and multivariate Cox regression analyses. In our model, the expressions of 5 immune genes, MIF, DEF6, OSM, MPO, AVPR1B, were used to stratify non-M3 AML patients' treatment outcome. A patient's risk score could be calculated as Risk Score=0.40081 × MIF (MIF expression) - 0.15201 × MPO + 0.78073 × DEF6 - 0.45192 × AVPR1B + 0.25912 × OSM. The area under the curve of the risk score signature was 0.8, 0.8, and 0.96 at 1 year, 3 years, and 5 years, respectively. The prognostic model was then validated internally by TCGA data and externally by GEO data. At last, the result of single-sample gene-set enrichment analysis demonstrated that compared with healthy samples, the abundance of non-turmeric immune cells was significantly repressed in AML. To summarize, we presented an immune-related 5-gene signature prognostic model in AML., Competing Interests: None., (AJTR Copyright © 2022.)
- Published
- 2022
38. Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia.
- Author
-
Dai Y, Huang J, Kuang P, Hu Y, Zeng Q, Zhang W, Li H, Wang F, Guo T, Zhang D, Yi D, Zheng Y, and Liu T
- Abstract
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) is a high-risk disease subtype with a dismal prognosis. Inhibiting BCR-ABL kinase alone is insufficient to eradicate Ph+ALL clones, and alternative BCR-ABL-dependent and -independent pathways need to be targeted as an effective strategy. Our study revealed that the combination of dasatinib and interferon-α showed synergistic activity against Ph+ALL, inducing mitochondrial dysfunction and causing necrosis-like cell lysis. Mechanistic studies showed that the induced cell death was caspase-3-independent. Canonical necroptosis signals, such as RIP1 and MLKL, were not activated; instead, the pyroptosis executor Gasdermin D was upregulated expression and activated. The expression levels of extracellular ATP and IL-1β were also upregulated, both of which are markers of pyroptotic cell death. In a murine Ph+ALL model, the dual drug treatment prolonged the survival of tumor-bearing mice. More importantly, we incorporated the dual drugs to maintenance therapy in 39 patients who were unfit for allogeneic stem cell transplantation (allo-HSCT). The median follow-up was 28.5 months, the 4-year disease-free survival and overall survival rates were 52.2% and 65.2%, respectively. Our data suggest that the combination of dasatinib and interferon-α has potential synergistic activity against Ph+ALL and shows promise as a maintenance therapy for Ph+ALL patients who are unfit for allo-HSCT., Competing Interests: None., (AJCR Copyright © 2022.)
- Published
- 2022
39. Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.
- Author
-
Luo H, Qin Y, Reu F, Ye S, Dai Y, Huang J, Wang F, Zhang D, Pan L, Zhu H, Wu Y, Niu T, Xiao Z, Zheng Y, and Liu T
- Subjects
- Adult, Disease-Free Survival, Female, Gene Expression Profiling, Humans, Induction Chemotherapy, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Leukemia, Promyelocytic, Acute diagnosis, Leukemia, Promyelocytic, Acute drug therapy, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute mortality, Male, Microarray Analysis, Prognosis, Survival Analysis, Leukemia, Myeloid, Acute diagnosis, Ubiquitin-Conjugating Enzymes analysis
- Abstract
Background: Previous research suggested that single gene expression might be correlated with acute myeloid leukemia (AML) survival. Therefore, we conducted a systematical analysis for AML prognostic gene expressions., Methods: We performed a microarray-based analysis for correlations between gene expression and adult AML overall survival (OS) using datasets GSE12417 and GSE8970. Positive findings were validated in an independent cohort of 50 newly diagnosed, non-acute promyelocytic leukemia (APL) AML patients by quantitative RT-PCR and survival analysis., Results: Microarray-based analysis suggested that expression of eight genes was each associated with 1-year and 3-year AML OS in both GSE12417 and GSE8970 datasets (p < 0.05). Next, we validated our findings in an independent cohort of AML samples collected in our hospital. We found that ubiquitin-conjugating enzyme E2E1 (UBE2E1) expression was adversely correlated with AML survival (p = 0.04). Multivariable analysis showed that UBE2E1
high patients had a significant shorter OS and shorter progression-free survival after adjusting other known prognostic factors (p = 0.03). At last, we found that UBE2E1 expression was negatively correlated with patients' response to induction chemotherapy (p < 0.05)., Conclusions: In summary, we demonstrated that UBE2E1 expression was a novel prognostic factor in adult, non-APL AML patients.- Published
- 2016
- Full Text
- View/download PDF
40. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
- Author
-
Lyu H, Huang J, Edgerton SM, Thor AD, He Z, and Liu B
- Subjects
- Animals, Breast Neoplasms enzymology, Breast Neoplasms genetics, Breast Neoplasms pathology, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Lapatinib, MCF-7 Cells, Mice, Mice, Transgenic, MicroRNAs genetics, MicroRNAs metabolism, Molecular Targeted Therapy, Phosphatidylinositol 3-Kinase metabolism, Proto-Oncogene Proteins c-akt metabolism, RNA Interference, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Receptor, ErbB-3 genetics, Receptor, ErbB-3 metabolism, Signal Transduction drug effects, Time Factors, Transfection, Tumor Burden drug effects, Antineoplastic Combined Chemotherapy Protocols pharmacology, Breast Neoplasms drug therapy, Cell Proliferation drug effects, Protein Kinase Inhibitors pharmacology, Quinazolines pharmacology, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-3 antagonists & inhibitors, Trastuzumab pharmacology
- Abstract
The kinase deficient erbB3 receptor frequently co-expresses and interacts with erbB2 in human breast cancer to activate the oncogenic signaling pathways, and thus promote breast cancer cell survival/proliferation. In the current study, we discovered that the expression of endogenous mouse erbB3 was increased in the mammary tumors-derived from wild type (wt) rat erbB2/neu-transgenic mice, and the co-expression of erbB2 and erbB3 significantly promoted mammary tumor proliferation in vivo. Co-immunoprecipitation assays detected a heterodimeric complex consisting of the transgene encoded protein rat erbB2 and the endogenous mouse erbB3 in the mammary tumors. Specific knockdown of mouse erbB3 dramatically inhibited proliferation of the mammary tumor cell lines-derived from the transgenic mice. Elevated expression of erbB3 protein, but not mRNA, was abserved in human breast cancer cells upon ectopic expression of erbB2. Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Furthermore, an anti-erbB3 monoclonal IgG1 antibody (Ab) in combination with Herceptin mainly inactivated Akt and significantly inhibited proliferation of erbB2-overexpressing breast cancer cells. Collectively, our data indicate that increased expression of erbB3 plays a pivotal role in activating downstream PI-3K/Akt pathway and promoting erbB2-driven mammary/breast tumorigenesis. Simultaneous targeting of erbB2 and erbB3 with two IgG1 Abs may be an effective strategy to treat breast cancer patients whose tumors overexpress both erbB2 and erbB3.
- Published
- 2015
41. MicroRNA regulation and therapeutic targeting of survivin in cancer.
- Author
-
Huang J, Lyu H, Wang J, and Liu B
- Abstract
Survivin, the smallest member of IAP (inhibitor of apoptosis) family, is a dual functional protein acting as a critical apoptosis inhibitor and key cell cycle regulator. Survivin is usually expressed in embryonic tissues during development and undetectable in most terminally differentiated tissues. Numerous studies demonstrate that survivin is selectively upregulated in almost all types of human malignancies and its overexpression positively correlates with poor prognosis, tumor recurrence, and therapeutic resistance. This differential expression of survivin in tumors and normal tissues draws a great interest to develop survivin-targeted therapy for cancer treatment. Nonetheless, the molecular mechanisms controlling survivin expression in malignant tumor cells have not been fully understood. While aberrant activation of receptor tyrosine kinases (RTKs) and the downstream signaling, such as PI-3K/Akt, MEK/MAPK, mTOR, and STAT pathways, have frequently been shown to upregulate survivin, recent data suggest that a class of noncoding RNAs, microRNAs (miRNAs) also play an important role in survivin dysregulation in human cancers. Here, we focus on survivin expression-regulated by specific miRNAs binding to the 3'-UTR of survivin mRNA, and summarize the latest advances on survivin-targeted therapy in clinical trials and the therapeutic potential of survivin-targeting miRNAs in cancer.
- Published
- 2014
42. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
- Author
-
Ma J, Lyu H, Huang J, and Liu B
- Subjects
- Animals, Carcinogenesis drug effects, Carcinogenesis genetics, Carcinogenesis metabolism, Drug Resistance, Neoplasm genetics, Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors, Extracellular Signal-Regulated MAP Kinases genetics, Extracellular Signal-Regulated MAP Kinases metabolism, Humans, Neoplasms drug therapy, Neoplasms metabolism, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-3 antagonists & inhibitors, Receptor, ErbB-3 metabolism, Signal Transduction drug effects, Antibodies, Neutralizing therapeutic use, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm drug effects, Gene Expression Regulation, Neoplastic, Neoplasms genetics, Receptor, ErbB-3 genetics
- Abstract
The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent targets for selective anti-cancer therapies because of their transmembrane location and pro-oncogenic activity. While several therapeutic agents against erbB2 and/or EGFR have been used in the treatment of human cancers with efficacy, there has been relatively less emphasis on erbB3 as a molecular target. Elevated expression of erbB3 is frequently observed in various malignancies, where it promotes tumor progression via interactions with other receptor tyrosine kinases (RTKs) due to its lack of or weak intrinsic kinase activity. Studies on the underlying mechanisms implicate erbB3 as a major cause of treatment failure in cancer therapy, mainly through activation of the PI-3 K/Akt, MEK/MAPK, and Jak/Stat signaling pathways as well as Src kinase. It is believed that inhibition of erbB3 signaling may be required to overcome therapeutic resistance and effectively treat cancers. To date, no erbB3-targeted therapy has been approved for cancer treatment. Targeting of erbB3 receptor with a monoclonal antibody (Ab) is the only strategy currently under preclinical study and clinical evaluation. In this review, we focus on the role of erbB3-initiated signaling in the development of cancer drug resistance and discuss the latest advances in identifying therapeutic strategies inactivating erbB3 to overcome the resistance and enhance efficacy of cancer therapeutics.
- Published
- 2014
- Full Text
- View/download PDF
43. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
- Author
-
Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, and Liu B
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms pathology, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p27 metabolism, Drug Resistance, Neoplasm, Drug Synergism, Enzyme Activation, Female, G1 Phase Cell Cycle Checkpoints drug effects, Humans, Mice, Mice, Nude, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-3 antagonists & inhibitors, Receptor, ErbB-3 immunology, Signal Transduction drug effects, Trastuzumab, Tumor Burden drug effects, Xenograft Model Antitumor Assays, Antineoplastic Combined Chemotherapy Protocols pharmacology, Breast Neoplasms drug therapy, Receptor, ErbB-3 metabolism
- Abstract
Background: Elevated expression of erbB3 receptor has been reported to induce resistance to therapeutic agents, including trastuzumab in erbB2-overexpressing breast cancer. Our recent studies indicate that erbB3 interacts with both erbB2 and IGF-1 receptor to form a heterotrimeric complex in trastuzumab-resistant breast cancer cells. Herein, we investigate the antitumor activity of MM-121/SAR256212, a fully human anti-erbB3 antibody (Ab), against two erbB2-overexpressing breast cancer cell lines resistant to trastuzumab., Methods: MTS-based proliferation assays were used to determine cell viability upon treatment of trastuzumab and/or MM-121/SAR256212. Cell cycle progression was examined by flow cytometric analysis. Western blot analyses were performed to determine the expression and activation of proteins. Tumor xenografts were established by inoculation of the trastuzumab-resistant BT474-HR20 cells into nude mice. The tumor-bearing mice were treated with trastuzumab and/or MM-121/SAR256212 via i.p injection to determine the Abs' antitumor activity. Immunohistochemical analyses were carried out to study the Abs' inhibitory effects on tumor cell proliferation and induction of apoptosis in vivo., Results: MM-121 significantly enhanced trastuzumab-induced growth inhibition in two sensitive and two resistant breast cancer cell lines. MM-121 in combination with trastuzumab resulted in a dramatic reduction of phosphorylated erbB3 (P-erbB3) and Akt (P-Akt) in the in vitro studies. MM-121 combined with trastuzumab did not induce apoptosis in the trastuzumab-resistant cell lines under our cell culture condition, rather induced cell cycle G1 arrest mainly associated with the upregulation of p27(kip1). Interestingly, in the tumor xenograft model established from the trastuzumab-resistant cells, MM-121 in combination with trastuzumab as compared to either agent alone dramatically inhibited tumor growth correlated with a significant reduction of Ki67 staining and increase of cleaved caspase-3 in the tumor tissues., Conclusions: The combination of MM-121 and trastuzumab not only inhibits erbB2-overexpressing breast cancer cell proliferation, but also promotes the otherwise trastuzumab-resistant cells undergoing apoptosis in an in vivo xenografts model. Thus, MM-121 exhibits potent antitumor activity when combined with trastuzumab under the studied conditions. Our data suggest that further studies regarding the suitability of MM-121 for treatment of breast cancer patients whose tumors overexpress erbB2 and become resistant to trastuzumab may be warranted.
- Published
- 2013
- Full Text
- View/download PDF
44. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.
- Author
-
Cai B, Wang S, Huang J, Lee CK, Gao C, and Liu B
- Abstract
Cladribine (2-CDA) is a well-known purine nucleoside analog with activities against lymphoproliferative disorders such as hairy cell leukemia (HCL). Bendamustine, a hybrid molecule of purine analog and alkylator, induces apoptosis via DNA damage response and inhibition of mitotic checkpoint. Their therapeutic potential in patients with multiple myeloma (MM), particularly those become resistant to traditional chemotherapeutic agents, remains unclear. Here we study the effects of cladribine or bendamustine on dexamethasone-sensitive (MM1.S) and -resistant (MM1.R) MM cells. MTS-based proliferation assays showed that cladribine and bendamustine exhibited similar anti-proliferation/anti-survival effects on MM1.S and MM1.R cells in a dose-dependent manner. The IC50s of cladribine were approximately 35.3 nmol/L and 58 nmol/L for MM1.S and MM1.R cells, respectively. The IC50s of bendamustine were approximately 119.8 μmol/L (MM1.S) and 138 μmol/L (MM1.R). An apoptotic-ELISA and western blot assays of PARP cleavage and activation of caspase-8 and caspase-3 indicated that cladribine or bendamustine induced apoptosis in both cell lines. Similar results were obtained with flow cytometric analysis showing that cladribine or bendamustine increased the sub-G1 population. Treatment with bendamustine but not cladribine also resulted in cell cycle S-phase arrest. Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response. Collectively, we demonstrate that cladribine and bendamustine exert potent inhibitory effects on dexamethasone-sensitive and -resistant MM cells in vitro. Our data suggest that MM patients, including those with dexamethasone resistance, may particularly benefit from cladribine or bendamustine.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.